Therapeutic Classification: urinary tract antispasmodics
Pharmacologic Classification: beta-adrenergic agonists
Absorption: 29–35% absorbed following oral administration.
Distribution: Widely distributed.
Metabolism/Excretion: Extensively metabolized, 6% excreted unchanged in urine (25 mg dose), remainder excreted in urine and feces as metabolites.
Half-Life: Adults: 50 hr; Children: 26–31 hr.
- The extended-release tablets and extended-release oral suspension are NOT interchangeable and should NOT be combined.
Overactive Bladder
- PO (Adults ): 25 mg once daily; may ↑ to 50 mg once daily, if needed, after 4–8 wk.
Renal Impairment
- PO (Adults ): eGFR 15–29 mL/min/m2: 25 mg once daily (max dose = 25 mg/day).
Hepatic Impairment
- PO (Adults ): Moderate hepatic impairment: 25 mg once daily (max dose = 25 mg/day).
Neurogenic Detrusor Overactivity
- PO (Children ≥3 yr and ≥35 kg): Extended-release tablets: 25 mg once daily; may ↑ to 50 mg once daily, if needed, after 4–8 wk. Extended-release oral suspension (granules): 48 mg once daily; may ↑ to 80 mg once daily, if needed after 4–8 wk.
- PO (Children ≥3 yr and 22–<35 kg): Extended-release oral suspension (granules): 32 mg once daily; may ↑ to 64 mg once daily, if needed after 4–8 wk.
- PO (Children ≥3 yr and 11–<22 kg): Extended-release oral suspension (granules): 24 mg once daily; may ↑ to 48 mg once daily, if needed after 4–8 wk.
Renal Impairment
- PO (Children ≥3 yr and ≥35 kg): eGFR 15–29 mL/min/m2: Extended-release tablets: 25 mg once daily (max dose = 25 mg/day); Extended-release oral suspension (granules): 48 mg once daily (max dose = 48 mg/day).
Renal Impairment
- PO (Children ≥3 yr and 22–<35 kg): eGFR 15–29 mL/min/m2: Extended-release oral suspension (granules): 32 mg once daily (max dose = 32 mg/day).
Renal Impairment
- PO (Children ≥3 yr and 11–<22 kg): eGFR 15–29 mL/min/m2: Extended-release oral suspension (granules): 24 mg once daily (max dose = 24 mg/day).
Hepatic Impairment
- PO (Children ≥3 yr and ≥35 kg): Moderate hepatic impairment: Extended-release tablets: 25 mg once daily (max dose = 25 mg/day); Extended-release oral suspension (granules): 48 mg once daily (max dose = 48 mg/day).
Hepatic Impairment
- PO (Children ≥3 yr and 22–<35 kg): Moderate hepatic impairment: Extended-release oral suspension (granules): 32 mg once daily (max dose = 32 mg/day).
Hepatic Impairment
- PO (Children ≥3 yr and 11–<22 kg): Moderate hepatic impairment: Extended-release oral suspension (granules): 24 mg once daily (max dose = 24 mg/day).
- Tablets and granules are different products. Do not interchange, substitute, or combine.
Overactive Bladder
- PO: Administer without regard to food.
- DNC: Swallow tablets whole with water; do not break, crush, or chew.
Neurogenic Detrusor Overactivity
- Pediatric patients weighing ≥35 kg may use tablets or granules. Administer as an extended-release oral suspension once daily.
- DNC: Swallow tablets whole with water; do not break, crush, or chew.
- Administer granules for patients weighing <35 kg. Granules are prepared as an extended-release oral suspension with a concentration of 8 mg/mL. Shake bottle for 1 min then let stand until foam on top of suspension is gone (about 1–2 min). Administer within 1 hr after preparation with food once daily; do not save dose for later.
